NH Hospital's innovative approach to mental health is based on the patient's biochemical makeup and gene-environment interfaces. Photo courtesy of NH Hospital

There's no one-size-fits-all solution to medical care. NH Hospital is bringing innovative technologies and functional medicine to patients in the Houston area. Using patients' biochemical makeup, the medical provider has created a unique service for Houstonians seeking a multi-pronged approach to behavioral health and substance use disorders.

The past year has been an incubator for mental health issues. Pandemic isolation, social distancing, financial instability, racial reckonings, and a massive death toll have posed an enormous threat to the mental wellbeing of people around the world. Experts predict a long-term spike in post-traumatic stress disorder (PTSD) cases as society grapples with the tragedies of the last year, but the toll is already here.

A recent Centers for Disease Control and Prevention (CDC) study found that the percentage of adults with recent symptoms of anxiety or depression increased from 36.4 to 41.5 percent between Aug. 19, 2020, and Feb. 1, 2021.

As the world waits for a moment to exhale after a catastrophic year, NH Hospital keeps busy serving patients struggling with both behavioral health and addiction during the pandemic. Outside of depression and anxiety, the facility also treats bipolar disorder, PTSD, codependency, and postpartum depression by using a multidisciplinary approach.

NH Hospital integrates traditional medicine with functional medicine with a mission of treating the root cause of an issue and not just the symptoms. From providing an on-site chef and nutritionist to stimulating patients with calming acoustic therapy, the facility blends unique treatment modalities that address the whole body rather than an isolated issue.

"With functional medicine, we find other avenues and ways to allow [patients] to heal and to change their behavior," explains Debbie Cormier, CEO of NH Hospital.

Using genetic markers as a roadmap to health

You can build the closet of Carrie Bradshaw's dreams online, buy bespoke cologne based on your body chemistry, monogram jewelry and clothing, and even get a Renaissance-style portrait of your family pet. Tailor-made options are ubiquitous; why not customize medical care?

"For years, the traditional way, we just gave people the same amount of meds, the same diets, the same everything," and wondered why some patients responded better or quicker than others, explains Cormier. For the unlucky patients who didn't get stellar results, she says doctors may have thought "they just have to deal with it" and wait. "We don't feel that you should have to just deal with it," she continues.

When treating a patient, NH Hospital doctors consider the genetic makeup of each patient to create a custom care plan. With tests as simple as a swab of the cheek, the facility can gather biochemical markers that can share valuable medical information like risk factors for diseases.

Cormier believes NH Hospital's ability to look at a patient's genetic background and "treat you as an individual," is a key factor that sets the facility apart. The hospital also focuses on understanding how your genes interact with your environment.

Think of gene-environment interactions as nature vs. nurture, an ideology that research suggests plays significant roles in the outset of mental illness. Genetic and environmental factors interact to influence phenotype, the observable characteristics you exhibit when your genotype and environment interact.

When these factors are off-balance, it can result in undesirable results. A 2001 study of Finnish twins studied the socio-geographic impact on adolescent alcohol use in urban and rural environments. While the frequency of alcohol use was the same in both settings, the factors that led adolescents to drink were entirely different. Genetic factors played a larger role in urban areas, whereas the shared environment had a greater influence in rural settings.

By applying various modalities based on genetic information, doctors aren't going in blind and "know you from the inside out," says Cormier.

When a patient comes in struggling with something as grappling as depression or anxiety, conditions they've seen an uptick in since the beginning of the pandemic, doctors will run a genetic test as well as traditional lab work. Cormier says some potential treatment paths may include photosynthesis therapy, hydration therapy and nutrition.

Dietetics meets tech

NH Hospital helps patients get micronutrient infusions, but its nutrition program provides an integrated approach to fueling the body with the help of a staff chef.

"We only have so much energy every day, and we choose how we use the energy but by getting your diet right, it starts to heal you in all kinds of ways," says Cormier.

While the physical repercussions of a poor diet like diabetes and heart disease are widely known, you may be surprised to hear that nutrition can affect mood disorders and harm brain cells. According to Harvard Health Publishing, refined sugars can lead to brain impairment, depression and oxidative stress — the free radicals produced when the body uses oxygen, which can damage cells. By focusing on a patient's nutrition, "the person has a better chance to heal, not only from the issue that is brought to us but to overall feel good," she says.

Counseling, cryotherapy, transcranial magnetic stimulation and cocoon therapy therapies are just some of the other methods NH Hospital doctors use to treat their patients.

Cormier recalls the recovery of a patient who was experiencing depression and using a wheelchair due to pain in her knees. She gradually gained the ability to walk without pain again after a months-long treatment plan of cryotherapy and micronutrient infusions.

"She said that we really changed her life because we gave her back her life. Now she's walking a mile a day around her block and she's able to do daily moving. She said she hadn't done that in years," says Cormier.

A mission to heal

Outside of neuropsychology, NH Hospital offers medical detox with monitoring from trained professionals and therapy plans for patients coming off of alcohol, methamphetamine, heroin, opioids like fentanyl and other prescription drugs.

Since the U.S. The Department of Health and Human Services declared the opioid epidemic as a public health emergency in 2017, nearly 841,000 people have died of an opioid overdose. Like anxiety and depression, addiction is also on the rise during the pandemic. A CDC survey found that 13 percent of respondents began using drugs during the pandemic or increased their use of illicit substances.

NH Hospital doctors provide micronutrients among other aides to help "build [patients] up] before taking them off the drugs, says Cormier. "We're just trying to make sure the patient feels safe and that if we're doing all these things, we continue to move them in a positive direction instead of just letting them sweat it out," she says.

"Our leadership here is committed to doing what it takes to help people whether they have behavioral, medical, or whatever [condition] brings them through our doors so that we make them have a better life," says Cormier.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Texas space co. takes giant step toward lunar excavator deployment

Out of this world

Lunar exploration and development are currently hampered by the fact that the moon is largely devoid of necessary infrastructure, like spaceports. Such amenities need to be constructed remotely by autonomous vehicles, and making effective devices that can survive the harsh lunar surface long enough to complete construction projects is daunting.

Enter San Antonio-based Astroport Space Technologies. Founded in San Antonio in 2020, the company has become a major part of building plans beyond Earth, via its prototype excavator, and in early February, it completed an important field test of its new lunar excavator.

The new excavator is designed to function with California-based Astrolab's Flexible Logistics and Exploration (FLEX) rover, a highly modular vehicle that will perform a variety of functions on the surface of the moon.

In a recent demo, the Astroport prototype excavator successfully integrated with FLEX and proceeded to dig in a simulated lunar surface. The excavator collected an average of 207 lbs (94kg) of regolith (lunar surface dust) in just 3.5 minutes. It will need that speed to move the estimated 3,723 tons (3,378 tonnes) of regolith needed for a lunar spaceport.

After the successful test, both Astroport and Astrolab expressed confidence that the excavator was ready for deployment. "Leading with this successful excavator demo proves that our technology is no longer theoretical—it is operational," said Sam Ximenes, CEO of Astroport.

"This is the first of many implements in development that will turn Astrolab's FLEX rover into the 'Swiss Army Knife' of lunar construction. To meet the infrastructure needs of the emerging lunar economy, we must build the 'Port' before the 'Ship' arrives. By leveraging the FLEX platform, we are providing the Space Force, NASA, and commercial partners with a 'Shovel-Ready' construction capability to secure the lunar high ground."

"We are excited to provide the mobility backbone for Astroport's groundbreaking construction technology," said Jaret Matthews, CEO of Astrolab, in a release. "Astrolab is dedicated to establishing a viable lunar ecosystem. By combining our FLEX rover's versatility with Astroport's civil engineering expertise, we are delivering the essential capabilities required for a sustainable lunar economy."

---

This article originally appeared on CultureMap.com.

Houston biotech co. raises $11M to advance ALS drug development

drug money

Houston-based clinical-stage biotechnology company Coya Therapeutics (NASDAQ: COYA) has raised $11.1 million in a private investment round.

India-based pharmaceuticals company Dr. Reddy’s Laboratories Inc. led the round with a $10 million investment, according to a news release. New York-based investment firm Greenlight Capital, Coya’s largest institutional shareholder, contributed $1.1 million.

The funding was raised through a definitive securities purchase agreement for the purchase and sale of more than 2.5 million shares of Coya's common stock in a private placement at $4.40 per share.

Coya reports that it plans to use the proceeds to scale up manufacturing of low-dose interleukin-2 (IL-2), which is a component of its COYA 302 and will support the commercial readiness of the drug. COYA 302 enhances anti-inflammatory T cell function and suppresses harmful immune activity for treatment of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s disease and Alzheimer’s disease.

The company received FDA acceptance for its investigational new drug application for COYA 302 for treating ALS and FTD this summer. Its ALSTARS Phase 2 clinical trial for ALS treatment launched this fall in the U.S. and Canada and has begun enrolling and dosing patients. Coya CEO Arun Swaminathan said in a letter to investors that the company also plans to advance its clinical programs for the drug for FTD therapy in 2026.

Coya was founded in 2021. The company merged with Nicoya Health Inc. in 2020 and raised $10 million in its series A the same year. It closed its IPO in January 2023 for more than $15 million. Its therapeutics uses innovative work from Houston Methodist's Dr. Stanley H. Appel.

New accelerator for AI startups to launch at Houston's Ion this spring

The Collectiv Foundation and Rice University have established a sports, health and wellness startup accelerator at the Ion District’s Collectiv, a sports-focused venture capital platform.

The AI Native Dual-Use Sports, Health & Wellness Accelerator, scheduled to formally launch in March, will back early-stage startups developing AI for the sports, health and wellness markets. Accelerator participants will gain access to a host of opportunities with:

  • Mentors
  • Advisers
  • Pro sports teams and leagues
  • University athletics programs
  • Health care systems
  • Corporate partners
  • VC firms
  • Pilot projects
  • University-based entrepreneurship and business initiatives

Accelerator participants will focus on sports tech verticals inlcuding performance and health, fan experience and media platforms, data and analytics, and infrastructure.

“Houston is quickly becoming one of the most important innovation hubs at the intersection of sports, health, and AI,” Ashley DeWalt, co-founder and managing partner of The Collectiv and founder of The Collectiv Foundation, said in a news release.

“By launching this platform with Rice University in the Ion District,” he added, “we are building a category-defining acceleration engine that gives founders access to world-class research, global sports properties, hospital systems, and venture capital. This is about turning sports-validated technology into globally scalable companies at a moment when the world’s attention is converging on Houston ahead of the 2026 World Cup.”

The Collectiv accelerator will draw on expertise from organizations such as the Rice-Houston Methodist Center for Human Performance, Rice Brain Institute, Rice Gateway Project and the Texas Medical Center.

“The combination of Rice University’s research leadership, Houston’s unmatched health ecosystem, and The Collectiv’s operator-driven investment platform creates a powerful acceleration engine,” Blair Garrou, co-founder and managing partner of the Mercury Fund VC firm and a senior adviser for The Collectiv, added in the release.

Additional details on programming, partners and application timelines are expected to be announced in the coming weeks.